Spooner R A, Deonarain M P, Savage P, Epenetos A A
Royal Postgraduate Medical School, Department of Clinical Oncology, Hammersmith Hospital, London.
Cell Biophys. 1993 Jan-Jun;22(1-3):225-42. doi: 10.1007/BF03033875.
We report bacterial expression of a single-chain antibody (ScFv) reactive against the haptens 4-hydroxy-3 nitrophenylacetic acid (NP) and 4-hydroxy-3-iodo-5-nitrophenylacetic acid (NIP) that is suitable for targeting to mammalian cells in vitro in a novel two-step targeting strategy. Hapten-derivatized primary antibodies of known specificity, bound to target cells, can capture the ScFv. Specificity resides in the interaction of the primary targeting antibody with the target and the interaction of the ScFv for NP/NIP, since the ScFv does not bind cells and nonderivatized antibodies bound at cells cannot capture the ScFv. The ScFv described here can therefore be considered as a universal agent for delivery of drugs, toxins, or radionuclides to any cell type for which a previously characterized antibody exists.
我们报道了一种单链抗体（ScFv）的细菌表达，该抗体可与半抗原4-羟基-3-硝基苯乙酸（NP）和4-羟基-3-碘-5-硝基苯乙酸（NIP）发生反应，适用于一种新型两步靶向策略中的体外靶向哺乳动物细胞。与靶细胞结合的具有已知特异性的半抗原衍生化一抗可以捕获ScFv。特异性存在于一级靶向抗体与靶标的相互作用以及ScFv与NP/NIP的相互作用中，因为ScFv不结合细胞，且结合在细胞上的未衍生化抗体无法捕获ScFv。因此，这里描述的ScFv可被视为一种通用试剂，用于将药物、毒素或放射性核素递送至任何存在先前已鉴定抗体的细胞类型。
